118P Can CD 47 be a targeted treatment in desmoid tumors?


Creative Commons License

Asarkaya E., Ipek S. A., Rüzgar H. A., Erayman M., Camadan Y. A., Ergözoğlu M., ...Daha Fazla

ESMO OPEN, cilt.10, sa.3, ss.20-21, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 3
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.esmoop.2025.104431
  • Dergi Adı: ESMO OPEN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.20-21
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: Desmoid tumors are aggressive tumors with unknown metastasis and

differentiation rates. Desmoid tumors with hereditary syndromes can develop in 5-

15% of patients with FAP syndrome. CD 47, also known as Integrin-associated protein,

CD47 has an important role in many biological processes such as immune cell activation,

cell migration and neural development. In this study, we aimed to evaluate the

correlation of CD47 expression with prognostic parameters in desmoid tumor cases.

Thus, we wanted to evaluate whether anti-CD 47 drugs, which have been studied

recently, can be used in desmoid tumors in the future.

Methods: Patients over the age of 18 who were histopathologically diagnosed with

desmoid tumor were included in the study. Demographic data of the patients,

treatments they received, tumor location, genetic tests if there was a concomitant

hereditary syndrome, and CD 47 expression in pathology preparations were evaluated.

In the immunohistochemical evaluation of CD47 expression; preparations were

evaluated in terms of the extent of expression in tumor cells and the intensity of

expression (low, moderate, high expression). Expression characteristics were evaluated

with demographic characteristics of the patients, accompanying hereditary

syndromes such as FAP, recurrence rates, and surgical responses.

Results: 128 patients diagnosed with desmoid tumor were included in the study. Only

9 of the 128 patients were diagnosed with hereditary familial polyposis syndrome,

while the other 121 patients were diagnosed with sporadic desmoid tumor. When the

CD 47 staining characteristics of our patients were evaluated as IHC in pathology

preparations, only 11 out of 128 patients showed staining characteristics. The staining

characteristics were slightly intense in all 11 patients. No significant relationship was

found between the staining characteristics and being a sporadic or hereditary disease.

None of our patients with a diagnosis of FAP showed CD 47 staining characteristics.

Again, no relationship was found between the number of recurrences and the CD 47

staining characteristics.

Conclusions: In our study, we could not detect CD 47 staining feature in both sporadic

desmoid tumors and FAP-related desmoid tumors.